Heart failure is a major public health burden in China. With a rapidly rising urban population and a growing trend in unhealthy lifestyles, heart failure is expected to affect a sizable population in the country. Although the treatment of acute heart failure (AHF) is dominated by older, cost-effective generic drugs, we expect the growing uptake of recently approved SGLT-2 inhibitors—dapagliflozin (Bristol Myers Squibb’s Farxiga) and empagliflozin (Boehringer Ingelheim’s Jardiance)—to boost the heart failure market. However, a significant unmet need exists for the treatment of chronic heart failure (CHF) with preserved ejection fraction, where treatment options are limited, representing an opportunity for drug developers. In addition, the ongoing reforms in the regulatory and A&R landscape of China are expected to encourage MNCs to enter the heart failure market.
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 50 surveys with cardiologists Supported by survey data collected for this and other DRG research epidemiology Diagnosed prevalence of heart failure in urban versus rural China; clinically relevant and market-relevant drug-treatable populations.
10-year, annualized, drug-level sales and patient shares of key heart failure regimens through 2029, based on primary and secondary market research to formulate bottom-up assumptions
Phase III/PR: 5+ drugs; Phase II: 3 drugs; coverage of select Phase I products